Show simple item record

The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

dc.contributor.authorKilickap, S.
dc.contributor.authorSakalar, T.
dc.contributor.authorTatli, A. M.
dc.contributor.authorBugdayci, F. Basol
dc.contributor.authorUysal, M.
dc.contributor.authorDemirkazik, A.
dc.contributor.authorBilgin, B.
dc.contributor.authorYildiz, B.
dc.contributor.authorKaraagac, M.
dc.contributor.authorOkutur, K.
dc.contributor.authorSakin, A.
dc.contributor.authorCabuk, D.
dc.contributor.authorEralp, Y.
dc.contributor.authorAlan, O.
dc.contributor.authorDemirci, U.
dc.contributor.authorCicin, I.
dc.contributor.authorOlmez, O. F.
dc.date.accessioned2021-03-04T08:43:25Z
dc.date.available2021-03-04T08:43:25Z
dc.identifier.citationKilickap S., Olmez O. F. , Cicin I., Demirci U., Alan O., Cabuk D., Sakalar T., Tatli A. M. , Bugdayci F. B. , Eralp Y., et al., "The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey", 43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.505
dc.identifier.othervv_1032021
dc.identifier.otherav_64b6aa2d-fb04-4fcc-9e9d-e116fc2657ab
dc.identifier.urihttp://hdl.handle.net/20.500.12627/70072
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectONKOLOJİ
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.titleThe efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
dc.typeBildiri
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume29
dc.contributor.firstauthorID155094


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record